[1]陈 杰.左旋肉碱治疗肝硬化并显性肝性脑病的效果观察[J].医学信息,2019,32(14):153-155.[doi:10.3969/j.issn.1006-1959.2019.14.051]
　CHEN Jie.Effect of L-carnitine on Liver Cirrhosis and Dominant Hepatic Encephalopathy[J].Journal of Medical Information,2019,32(14):153-155.[doi:10.3969/j.issn.1006-1959.2019.14.051]
点击复制

左旋肉碱治疗肝硬化并显性肝性脑病的效果观察()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年14期
页码:
153-155
栏目:
药物与临床
出版日期:
2019-07-15

文章信息/Info

Title:
Effect of L-carnitine on Liver Cirrhosis and Dominant Hepatic Encephalopathy
文章编号:
1006-1959（2019）14-0153-03
作者:
陈 杰
天津市宝坻区人民医院消化内科，天津 301800
Author(s):
CHEN Jie
Department of Gastroenterology,People's Hospital of Baodi District,Tianjin 301800,China
关键词:
左旋肉碱; 肝硬化; 显性肝性脑病
Keywords:
Key words：L-carnitine; Cirrhosis; Dominant hepatic encephalopathy
分类号:
R575
DOI:
10.3969/j.issn.1006-1959.2019.14.051
文献标志码:
A
摘要:
目的 探讨左旋肉碱治疗肝硬化并显性肝性脑病患者的临床疗效。方法 选择2011年3月~2018年6月天津市宝坻区人民医院收治的84例肝硬化并发肝性脑病显性症状，且住院治疗＞1周的患者作为研究对象，随机分为左旋肉碱组和对照组，每组42例。对照组接受常规治疗，左旋肉碱组在常规治疗基础上联合应用左旋肉碱。比较治疗7 天时两组患者肝性脑病West-Haven分级、NCT-A时间、血氨情况，以及两组住院天数、随访6周时肝性脑病复发情况。结果 治疗7天时左旋肉碱组NCT-A时间为（52.31±17.92）s ，低于对照组的（61.32±18.24）s（P＜0.05）；空腹静脉血氨水平为（45.23±27.42）μmol/L，低于对照组的 （60.44±25.43）μmol/L（P＜0.05）；左旋肉碱组HE分级为（1.47±0.51），与对照组的（1.43±0.54）比较，差异无统计学意义（P＞0.05）。两组患者平均住院日［（8.32±3.60）d vs（9.12±5.81）d］及随访6周肝性脑病早期复发率（35.71% vs 28.57%）分别比较，差异均无统计学意义（P＞0.05）。结论 左旋肉碱虽能降低肝硬化并显性肝性脑病患者血氨水平、改善NCT-A时间，但不能改善肝性脑病严重程度分级、降低住院日及肝性脑病复发率，其在肝硬化并显性肝性脑病中的应用价值有待进一步证实。
Abstract:
Abstract：Objective To investigate the clinical efficacy of L-carnitine in patients with liver cirrhosis and dominant hepatic encephalopathy.Methods 84 patients with hepatic cirrhosis complicated with hepatic encephalopathy admitted to Tianjin Baodi District People's Hospital from March 2011 to June 2018 were enrolled. Patients with hospitalization >1 week were randomly divided into L-carnitine group. And the control group, 42 cases in each group. The control group received conventional treatment, and the L-carnitine group was combined with L-carnitine on the basis of conventional treatment. The West-Haven grade, NCT-A time, blood ammonia status of the hepatic encephalopathy in the two groups were compared at 7 days of treatment, and the number of hospital stays in the two groups and the recurrence of hepatic encephalopathy at 6 weeks follow-up. Results The time of NCT-A in the L-carnitine group was (52.31±17.92) s at 7 days of treatment, which was lower than that of the control group (61.32±18.24) s (P<0.05). The fasting venous blood ammonia level was (45.23±27.42) μmol/L,lower than the control group (60.44±25.43) μmol/L (P<0.05); The HE grade in the L-carnitine group was (1.47±0.51), which was not significantly different from that in the control group (1.43±0.54) (P>0.05). The average hospitalization days of the two groups [(8.32±3.60) d vs (9.12±5.81) d] and the early recurrence rate of hepatic encephalopathy at 6 weeks follow-up (35.71% vs 28.57%) were compared. There was no significant difference in the difference (P>0.05). Conclusion L-carnitine can reduce the blood ammonia level and improve the time of NCT-A in patients with liver cirrhosis and dominant hepatic encephalopathy, but it can not improve the severity of hepatic encephalopathy, reduce the hospitalization day and the recurrence rate of hepatic encephalopathy. The value of application in dominant hepatic encephalopathy needs further confirmation.

参考文献/References:

[1]Butterworth RF.Hepatic Encephalopathy in Cirrhosis:Pathology and Pathophysiology[J].Drugs,2019,79(Suppl 1):17-21. [2]Malaguarnera M.Acetyl-L-carnitine in hepatic encephalopathy[J].Metab Brain Dis,2013,28(2):193-199. [3]中华医学会肝病学分会.肝硬化肝性脑病诊疗指南[J].中华内科杂志,2018,57(10):705-718. [4]Acharya C,Bajaj JS.Current Management of Hepatic Encephalopathy[J].Am J Gastroenterol,2018,113(11):1600-1612. [5]陈东风,孙文静.肝性脑病发病机制的研究进展[J].中华肝脏病杂志,2014,22(2):84-85. [6]Ott P,Vilstrup H.Cerebral effects of ammonia in liver disease:current hypotheses[J].Metab Brain Dis,2014,29(4):901-911. [7]Rangroo VT,Thrane AS,Wang F,et al.Ammonia triggers neuronal disinhibition and seizures by impairing astrocyte potassium buffering[J].Nat Med,2013,19(12):1643-1648. [8]American Association for the Study of Liver Diseases,European Association for the Study of the Liver.Hepatic encephalopathy in chronic liver disease:2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases[J].J Hepatol,2014,61(3):642-659. [9]王峻瑶,刘玉兰.肝性脑病研究现状与展望[J].中华肝脏病杂志,2014,22(2):81-83. [10]Malaguarnera M,Pistone G,Astuto M,et al.Effects of L-acetylcarnitine on cirrhotic patients with hepatic coma:randomized double-blind,placebo-controlled trial[J].Dig Dis Sci,2006,51(12):2242-2247. [11]Jiang Q,Jiang G,Shi KQ,et al.Oral acetyl-L-carnitine treatment in hepatic encephalopathy: view of evidence-based medicine[J].Ann Hepatol,2013,12(5):803-809. [12]Tajiri K,Futsukaichi Y,Kobayashi S,et al.L-Carnitine for the Treatment of Overt Hepatic Encephalopathy in Patients with Advanced Liver Cirrhosis[J].J Nutr Sci Vitaminol(Tokyo), 2018,64(5):321-328. [13]Wijdicks EF.Hepatic Encephalopathy[J].N Engl J Med,2016,375(17):1660-1670. [14]Acharya C,Bajaj JS.Current Management of Hepatic Encephalopathy[J].Am J Gastroenterol,2018,113(7):1600-1612.

相似文献/References:

[1]崔 洁.凝血酶原时间与血小板检验方式对诊断肝硬化疾病的临床价值研究[J].医学信息,2018,31(04):150.[doi:10.3969/j.issn.1006-1959.2018.04.055]
　CUI Jie.Study on the Clinical Value of Prothrombin Time and Platelet Examination in the Diagnosis of Liver Cirrhosis[J].Journal of Medical Information,2018,31(14):150.[doi:10.3969/j.issn.1006-1959.2018.04.055]
[2]祁兴顺,周新苗,许向波,等.肝硬化患者应用特利加压素治疗期间发生 低钠血症的现状研究[J].医学信息,2018,31(09):1.[doi:10.3969/j.issn.1006-1959.2018.09.001]
[3]张铁彪,刘建华,马长顺.肺癌肿瘤标记物结合胸部CT检查肺结节的定性分析[J].医学信息,2022,35(10):171.[doi:10.3969/j.issn.1006-1959.2022.10.044]
　ZHANG Tie-biao,LIU Jian-hua,MA Chang-shun.Qualitative Analysis of Lung Cancer Tumor Markers Combined with Chest CT Examination of Pulmonary Nodules[J].Journal of Medical Information,2022,35(14):171.[doi:10.3969/j.issn.1006-1959.2022.10.044]
[4]赵华莹,李运泽,韦天灵,等.肝硬化合并门静脉血栓形成的危险因素分析[J].医学信息,2019,32(03):86.[doi:10.3969/j.issn.1006-1959.2019.03.026]
　ZHAO Hua-ying,LI Yun-ze,WEI Tian-ling,et al.Analysis of Risk Factors for Cirrhotic Patients with Portal Vein Thrombosis[J].Journal of Medical Information,2019,32(14):86.[doi:10.3969/j.issn.1006-1959.2019.03.026]
[5]桂志兵,汪文生.红细胞分布宽度与血小板计数比值在乙型肝炎肝硬化患者病情评估中的作用[J].医学信息,2018,31(20):65.[doi:10.3969/j.issn.1006-1959.2018.20.019]
　GUI Zhi-bing,WANG Wen-sheng.The Role of Red Blood Cell Distribution Width and Platelet Ratio in the Evaluation of Patients with Hepatitis B Cirrhosis[J].Journal of Medical Information,2018,31(14):65.[doi:10.3969/j.issn.1006-1959.2018.20.019]
[6]王晓刚.利拉鲁肽联合胰岛素泵对2 型糖尿病合并肝硬化患者血糖代谢及肝纤维化的影响[J].医学信息,2018,31(20):136.[doi:10.3969/j.issn.1006-1959.2018.20.041]
　WANG Xiao-gang.Effects of Liraglutide Combined with Insulin Pump on Blood Glucose Metabolism and Liver Fibrosis in Patients with Type 2 Diabetes Mellitus Complicated with Cirrhosis[J].Journal of Medical Information,2018,31(14):136.[doi:10.3969/j.issn.1006-1959.2018.20.041]
[7]张宏程.生长抑素联合泮托拉唑治疗肝硬化合并上消化道出血的疗效观察[J].医学信息,2019,32(03):153.[doi:10.3969/j.issn.1006-1959.2019.03.050]
　ZHANG Hong-cheng.Therapeutic Effect of Somatostatin Combined with Pantoprazole on Hepatic Cirrhosis Complicated with Upper Gastrointestinal Hemorrhage[J].Journal of Medical Information,2019,32(14):153.[doi:10.3969/j.issn.1006-1959.2019.03.050]
[8]姜海燕.双歧杆菌四联活菌治疗对肝硬化患者肝功能、细胞因子及肠道菌群的影响[J].医学信息,2022,35(12):156.[doi:10.3969/j.issn.1006-1959.2022.12.038]
　JIANG Hai-yan.Effect of Quadruple Viable Bifidobacterium Treatment on Liver Function, Cytokines and Intestinal Flora in Patients with Liver Cirrhosis[J].Journal of Medical Information,2022,35(14):156.[doi:10.3969/j.issn.1006-1959.2022.12.038]
[9]张许林,余泽波.肝硬化上消化道出血的输血治疗进展[J].医学信息,2019,32(08):85.[doi:10.3969/j.issn.1006-1959.2019.08.025]
　ZHANG Xu-lin,YU Ze-bo.Progress in Transfusion Therapy for Upper Gastrointestinal Hemorrhage[J].Journal of Medical Information,2019,32(14):85.[doi:10.3969/j.issn.1006-1959.2019.08.025]
[10]曹 宇,何其顺,郭雅雯,等.延时扫描对肝硬化患者肝脏增强CT检查中动脉期时相的影响[J].医学信息,2020,33(01):161.[doi:10.3969/j.issn.1006-1959.2020.01.053]
　CAO Yu,HE Qi-shun,GUO Ya-wen,et al.Effect of Delayed Scanning on the Phase of the Middle Arterial Phase of Liver Enhanced CT in Patients with Cirrhosis[J].Journal of Medical Information,2020,33(14):161.[doi:10.3969/j.issn.1006-1959.2020.01.053]

更新日期/Last Update: 2019-07-15